Q3 Earnings Estimate for MLTX Issued By Wedbush

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities research analysts at Wedbush issued their Q3 2024 earnings estimates for shares of MoonLake Immunotherapeutics in a note issued to investors on Monday, November 4th. Wedbush analyst Y. Zhong expects that the company will earn ($0.35) per share for the quarter. Wedbush currently has a “Strong-Buy” rating on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.54) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics’ Q4 2024 earnings at ($0.38) EPS, FY2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.82) EPS, FY2027 earnings at ($1.59) EPS and FY2028 earnings at $0.38 EPS.

Other equities research analysts have also issued research reports about the stock. Wolfe Research lowered shares of MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a research note on Monday, August 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $62.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. Cantor Fitzgerald restated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, October 15th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.73.

MoonLake Immunotherapeutics Stock Performance

MLTX opened at $51.48 on Thursday. MoonLake Immunotherapeutics has a 1 year low of $35.53 and a 1 year high of $64.98. The stock’s 50 day simple moving average is $49.19 and its 200 day simple moving average is $45.28.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.11). During the same quarter in the prior year, the company posted ($0.23) EPS.

Insider Activity at MoonLake Immunotherapeutics

In related news, Director Simon Sturge sold 171,000 shares of the stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $53.72, for a total value of $9,186,120.00. Following the completion of the sale, the director now owns 171,980 shares of the company’s stock, valued at approximately $9,238,765.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 12.02% of the stock is owned by corporate insiders.

Institutional Trading of MoonLake Immunotherapeutics

A number of large investors have recently modified their holdings of the stock. Victory Capital Management Inc. boosted its holdings in shares of MoonLake Immunotherapeutics by 24.7% in the 3rd quarter. Victory Capital Management Inc. now owns 217,839 shares of the company’s stock valued at $10,983,000 after buying an additional 43,157 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in MoonLake Immunotherapeutics by 1.9% in the 3rd quarter. GSA Capital Partners LLP now owns 22,127 shares of the company’s stock valued at $1,116,000 after purchasing an additional 403 shares in the last quarter. AlphaCentric Advisors LLC purchased a new stake in shares of MoonLake Immunotherapeutics in the third quarter valued at approximately $706,000. Harbor Capital Advisors Inc. grew its stake in shares of MoonLake Immunotherapeutics by 100.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 77,468 shares of the company’s stock worth $3,906,000 after purchasing an additional 38,779 shares during the period. Finally, Rice Hall James & Associates LLC purchased a new position in MoonLake Immunotherapeutics in the third quarter valued at about $3,805,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.